Recent News

• 11.24.2025 - Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
• 11.14.2025 - Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
• 11.10.2025 - Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
• 10.20.2025 - Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
• 10.07.2025 - Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
• 09.19.2025 - Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
• 09.19.2025 - Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
• 09.02.2025 - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 09.02.2025 - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 08.12.2025 - Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

Recent Filings

• 11.24.2025 - EX-99.1 EX-99.1
• 11.24.2025 - 8-K Current report
• 11.24.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.14.2025 - EX-99.1 EX-99.1
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]